New imaging agent could sharpen prostate cancer detection
NCT ID NCT06101927
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study tested a new radioactive tracer called [99mTc]Tc-BQ0413 in 10 men with prostate cancer. The tracer was injected once, and SPECT scans were taken over 24 hours to see where it goes in the body and how safe it is. The goal is to develop a better imaging tool for prostate cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Technetium-99m BQ0413 ([99mTc]Tc-BQ0413) - a radioactive tracer for imaging
- What this could lead to
- If successful, this could lead to a new imaging method to better detect and monitor prostate cancer using SPECT scans.
- What could go wrong
- This is a very early Phase 1 study with only 10 participants, so results may not apply broadly. The tracer's imaging accuracy compared to standard methods is still unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
TomskNRMC
Tomsk, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?